These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 19707964)

  • 1. [Microalbuminuria and albuminuria: differential diagnosis and consequences for treatment].
    Koziolek MJ; Bramlage CP; Vasko R; Grupp C; Müller GA
    Dtsch Med Wochenschr; 2009 Aug; 134(34-35):1681-5. PubMed ID: 19707964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Microalbuminuria is an early marker for increased morbidity and mortality].
    Bramlage P; Wittchen HU; Pittrow D; Dikow R; Kirch W; Lehnert H; Ritz E
    Fortschr Med Orig; 2003 Feb; 121 Suppl 1():28-32. PubMed ID: 14732947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians.
    Bakris GL; Kuritzky L
    Postgrad Med; 2009 Jul; 121(4):51-60. PubMed ID: 19641270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microalbuminuria and cardiovascular risk.
    Karalliedde J; Viberti G
    Am J Hypertens; 2004 Oct; 17(10):986-93. PubMed ID: 15485765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microalbuminuria as a risk factor: the influence of renin-angiotensin system blockade.
    Menne J; Chatzikyrkou C; Haller H
    J Hypertens; 2010 Oct; 28(10):1983-94. PubMed ID: 20634721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microalbuminuria and cardiovascular disease.
    Weir MR
    Clin J Am Soc Nephrol; 2007 May; 2(3):581-90. PubMed ID: 17699466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent microalbuminuria after treatment with renin-angiotensin axis blockers: causes and results of treatment intensification.
    Robles NR; Velasco J; Espinosa J; Mena C; Angulo E;
    J Renin Angiotensin Aldosterone Syst; 2011 Sep; 12(3):333-9. PubMed ID: 20647247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Slowing progression along the renal disease continuum.
    Kopyt NP
    J Am Osteopath Assoc; 2005 Apr; 105(4):207-15. PubMed ID: 15928338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual renin-angiotensin system blockade and kidney disease.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Pfeffer MA
    J Am Coll Cardiol; 2009 Jul; 54(3):278-9; author reply 279-80. PubMed ID: 19589445
    [No Abstract]   [Full Text] [Related]  

  • 13. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U; Deedwania PC
    Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum?
    Schmieder RE
    J Hypertens Suppl; 2006 Apr; 24(2):S31-5. PubMed ID: 16601559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal disease: a common and a silent killer.
    de Zeeuw D
    Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S27-35. PubMed ID: 18580863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy of renin-angiotensin blockade in patients receiving dialysis.
    Suzuki H
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):397-405. PubMed ID: 19491138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hypertension in patients with diabetes].
    Poulsen PL; Hansen KW; Gaede PH; Rossing P
    Ugeskr Laeger; 2009 Jun; 171(24):2031-4. PubMed ID: 19523370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin-angiotensin system blockade and reduction of cardiovascular risk: future perspectives.
    de la Sierra A
    Expert Rev Cardiovasc Ther; 2011 Dec; 9(12):1585-91. PubMed ID: 22103877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart and kidney: fatal twins?
    Ritz E
    Am J Med; 2006 May; 119(5 Suppl 1):S31-9. PubMed ID: 16563946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point.
    Messerli FH
    J Am Coll Cardiol; 2009 Feb; 53(6):468-70. PubMed ID: 19195602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.